Quality of life and survival in advanced cervical cancer: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 125, Issue 2, 2012, Pages 315-319

  Chase, Dana M ^a   Huang, Helen Q ^b   Wenzel, Lari ^c   Cella, David ^d   McQuellon, Richard ^e   Long, Harry J ^f   Moore, David H ^g   Monk, Bradley J ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e WAKE FOREST BAPTIST HEALTH   (United States)

^f MAYO CLINIC   (United States)

^g Gynecologic Oncology of Indiana   (United States)

Author keywords

Cervical cancer; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GEMCITABINE; NAVELBINE; PACLITAXEL; RADIOSENSITIZING AGENT; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONFERENCE PAPER; EMOTION; FEMALE; HEALTH; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECURRENT CANCER; SOCIAL ASPECT; UTERINE CERVIX CANCER; WELLBEING;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 84862776638     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.01.047     Document Type: Conference Paper

References (28)

1. Moore DH, Blessing JA, McQuellon R, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2004;22:3113-9. (Pubitemid 41103724)
2. Long HJ, Bundy BN, Grendys Jr EC, Benda JA, McMeekin DS, Sorosky J, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 2005;23: 4626-33. (Pubitemid 46224065)
3. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III trial of four cisplatin containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009;27:4649-55.
4. Monk BJ, Huang HQ, Cella D, Long III HJ. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005;23:4617-25. (Pubitemid 46224064)
5. McQuellon RP, Thaler HT, Cella D, Moore DH. Quality of life (QoL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2006;101:296-304.
6. Long III HJ, Monk BJ, Huang HQ, Grendys Jr EC, McMeekin DS, Sorosky J, et al. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2006;100:537-43. (Pubitemid 43246869)
7. Monk BJ, Tian C, Rose PG, Lanciano R. Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials. Gynecol Oncol 2007;105:427-33. (Pubitemid 46613901)
8. Waggoner SE, Darcy KM, Fuhrman B, Parham G, Lucci III J, Monk BJ, et al. Association between cigarette smoking and prognosis in locally advanced cervical carcinoma treated with chemoradiation: a Gynecologic Oncology Group study. Gynecol Oncol 2006;103:853-8. (Pubitemid 44821303)
9. Moore DH, Tian C, Monk BJ, Long HJ, Omura GA, Bloss JD. Factors predictive of response to cisplatin-based chemotherapy in stage IVB persistent or recurrent cervical carcinoma: a multivariate analysis of three Gynecologic Oncology Group trials. Gynecol Oncol 2010;116:44-9.
10. Wenzel L, Huang HQ, Monk BJ, Rose PG, Cella D. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2005;23:5605-12.
11. Cella D, Huang HQ, Monk BJ, Wenzel L, Benda J, McMeekin DS, et al. Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2010;119:531-7.
12. Coyne JC, Pajak TF, Harris J, Konski A, Movsas B, Ang K, et al. Emotional well-being does not predict survival in head and neck cancer patients: a radiation therapy oncology group study. Cancer 2007;110:2568-75. (Pubitemid 350176515)
13. Cox DR. Regression models and life tables. J Royal Stat Soc, Series B 1972;20: 187-220 with discussion.
14. Cox DR. Partial likelihood. Biometrika 1975;62:269-76.
15. Efron B. The efficiency of cox's likelihood function for censored data. J Am Stat Assoc 1977;72:557-65.
16. Siddiqui F, Pajak TF, Watkins-Bruner D, Konski AA, Coyne JC, Gwede CK, et al. Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis. Int J Radiat Oncol Biol Phys 2008;70:353-60.
17. Dharma-Wardene M, Au HJ, Hanson J, Dupere D, Hewitt J, Feeny D. Baseline FACTG score is a predictor of survival for advanced lung cancer. Qual Life Res 2004;13: 1209-16. (Pubitemid 39157332)
18. Efficace F, Bottomley A, Smit EF, Lianes P, Legrand C, Debruyne C, et al. Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol 2006;17:1698-704. (Pubitemid 44680892)
19. Brown DJ, McMillan DC, Milroy R. The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. Cancer 2005;103:377-82. (Pubitemid 40129298)
20. Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 2008;26: 1355-63.
21. Ashing-Giwa KT, Lim JW, Tang J. Surviving cervical cancer: does health-related quality of life influence survival? Gynecol Oncol 2010;118:35-42.
22. Osoba D. Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 1994;12:608-16. (Pubitemid 24079906)
23. Osoba D. Measuring the effect of cancer on health-related quality of life. Pharmacoeconomics 1995;7:308-19.
24. Rummans TA, Clark MM, Sloan JA, Frost MH, Bostwick JM, Atherton PJ, et al. Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: a randomized controlled trial. J Clin Oncol 2006;24: 635-42. (Pubitemid 46630427)
25. Bakitas M, Lyons KD, Hegel MT, Balan S, Brokaw FC, Seville J, et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA 2009;302:741-9.
26. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733-42.
27. Nelson EL, Wenzel LB, Osann K, Dogan-Ates A, Chantana N, Reina-Patton A, et al. Stress, immunity, and cervical cancer: biobehavioral outcomes of a randomized clinical trial [corrected]. Clin Cancer Res 2008;14:2111-8. (Pubitemid 351551123)
28. Dubois D, Dhawan R, van de Velde H, Esseltine D, Gupta S, Viala M, et al. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J Clin Oncol 2006;24:976-82. (Pubitemid 46638852)